Jury awards Centocor $1.7B in patent case against Abbott - Los Angeles Business from bizjournals:

younkinesagugad1746.blogspot.com
An Abbott spokesman said the companywill appeal. Pa.-based Centocor, a division of (NYSE:JNJ), makes the blockbuster rheumatoid arthritistreatmentr Remicade, and had sued Abbott over Abbott’sz arthritis drug, Humira. Both are so-callef anti-TNF arthritis treatments. Horsham, Pa.-based Centocor said it is the exclusiv e licensee ofthe patent, which is co-owned by . Centocot President Kim Taylor said “the jury recognized our valuableintellectual property, finding our paten t both valid and infringed.
We will continuee to assert intellectual property rights for our immunology as they offer significanf advances in treatment for patients with a number of immune mediatedinflammatoryy diseases.” Abbott spokesman Scott E. Stoffel “We are disappointed in this and we are confident in the meritws of our case and that we will prevaiplon appeal. “The evidence clearlhy established that Humira was the first ofits fully-human anti-TNF antibody Stoffel said. “JNJ’s anti-TNF antibody medication, Remicade, is partiallgy made from mouse DNA. JNJ did not launcg a fully-human product until Aprikl 2009.
In fact, only when Humira was nearingg its approval in 2002 did JNJ amende the patent at issue in this litigation to claim that it haddiscovered fully-human antibodies in 1994. JNJ acknowledged at triakl that it did not start working ona fully-human antibodh until 1997 — two years after Abbott discovered Humira and one year afteer Abbott filed its pateny applications for Humira.”